Corona Remedies Ltd

Fri 16/10/2026,15:59:33 | NSE : CORONA

₹2003.90-40.90 (-2.00%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 2044.40

Previous Close

₹ 2044.80

Volume

112439

Mkt Cap ( ₹ Cr)

₹ 12255.87

High

₹ 2065.40

Low

₹ 1980.00

52 Week High

₹ 2292.40

52 Week Low

₹ 1336.60

Book Value Per Share

₹ 131.94

Dividend Yield

0.49

Face Value

₹ 10.00

What's Your Call?

Collective community sentiment on Corona Remedies Ltd

Your Vote -

Buy

50.00%

Hold

0.00%

Sell

50.00%

50.00%

2 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

2003.90

129

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

129

Option Chain

Analyzes market sentiment, predicts Corona Remedies Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Corona Remedies - Analysts/Institutional Investor Meet/Con. Call Updates

    16 Oct 2026, 1:01PM CORONA Remedies Limited has informed the Exchange about Schedule of meet

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    16 Oct 2026, 12:57PM Intimation for Schedule of Analyst / Investor Conference

  • Corona Remedies - Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results On Standalone And Co

    16 Oct 2026, 12:22PM Corona Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and

  • Corona Remedies has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2026

    7 Oct 2026, 8:20PM As of September 2026, 69.00% is owned by Indian Promoters and 31.00% by Public. <p align=justify> Institutional holds 20.65% (Insurance Companies 0.25

  • Corona Remedies - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    5 Oct 2026, 3:05PM Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026

  • Corona Remedies - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    5 Oct 2026, 3:00PM CORONA Remedies Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Corona Remedies - Credit Rating

    30 Sep 2026, 7:20PM CORONA Remedies Limited has informed the Exchange about Credit Rating

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Credit Rating

    30 Sep 2026, 7:16PM Credit Rating

  • Corona Remedies - Trading Window

    28 Sep 2026, 4:57PM CORONA Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,

  • Corona Remedies - Analysts/Institutional Investor Meet/Con. Call Updates

    18 Sep 2026, 3:00PM CORONA Remedies Limited has informed the Exchange about Schedule of meet

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    18 Sep 2026, 2:56PM Intimation of participation in Analyst / Investor meet

  • Corona Remedies - Clarification On Movement In Volume

    10 Sep 2026, 12:09PM Reply to Clarification

  • Corona Remedies - Clarification sought from Corona Remedies Ltd

    10 Sep 2026, 11:08AM The Exchange has sought clarification from Corona Remedies Ltd on September 10, 2026, with reference to Movement in Volume. <BR><BR>The reply is await

  • Corona Remedies - Spurt in Volume

    9 Sep 2026, 8:36PM Significant increase in volume has been observed in CORONA Remedies Limited. The Exchange, in order to ensure that investors have latest relevant info

  • Corona Remedies - Spurt in Volume

    9 Sep 2026, 5:52PM Significant increase in volume has been observed in CORONA Remedies Limited. The Exchange, in order to ensure that investors have latest relevant info

  • Corona Remedies - Analysts/Institutional Investor Meet/Con. Call Updates

    20 Aug 2026, 5:21PM CORONA Remedies Limited has informed the Exchange about Schedule of meet

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    20 Aug 2026, 5:19PM Intimation of participation in Analyst / Investor Conference

  • Corona Remedies - Analysts/Institutional Investor Meet/Con. Call Updates

    10 Aug 2026, 5:57PM CORONA Remedies Limited has informed the Exchange about Transcript

  • Corona Remedies - Analysts/Institutional Investor Meet/Con. Call Updates

    10 Aug 2026, 11:26AM CORONA Remedies Limited has informed the Exchange about Schedule of meet

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    10 Aug 2026, 5:55PM Transcript of Earnings Call with Analyst / Investor on Unaudited Financial Results for the first quarter and three months ended June 30, 2026

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    10 Aug 2026, 11:20AM Intimation for Schedule of Analysts / Investor Conference

  • Corona Remedies - Updates

    7 Aug 2026, 3:54PM CORONA Remedies Limited has informed the Exchange regarding 'Machine Readable Financial results for Q1 2026-27'.

  • Corona Remedies - Analysts/Institutional Investor Meet/Con. Call Updates

    3 Aug 2026, 4:25PM CORONA Remedies Limited has informed the Exchange about Link of Recording

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    3 Aug 2026, 4:21PM Audio Recording of Q1 FY27 Earnings Conference Call with Analysts / Investors

  • Corona Remedies - Copy of Newspaper Publication

    1 Aug 2026, 10:48AM CORONA Remedies Limited has informed the Exchange about Copy of Newspaper Publication

  • Corona Remedies - Investor Presentation

    31 Jul 2026, 7:37PM CORONA Remedies Limited has informed the Exchange about Investor Presentation

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Investor Presentation

    31 Jul 2026, 7:35PM Analyst/Investor presentation

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    31 Jul 2026, 5:43PM Press Release on Financial Results for Q1FY27

  • Corona Remedies - Press Release

    31 Jul 2026, 5:37PM CORONA Remedies Limited has informed the Exchange regarding a press release dated July 31, 2026, titled ""Press Release on Unaudited financial results

  • Corona Remedies - Outcome of Board Meeting

    31 Jul 2026, 5:32PM CORONA Remedies Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

  • Corona Remedies - Unaudited Financial Results For The First Quarter And Three Months Ended June 30, 2026

    31 Jul 2026, 5:28PM Unaudited Financial Results for the first quarter and three months ended June 30, 2026

  • Corona Remedies - Board Meeting Outcome for Outcome Of Board Meeting

    31 Jul 2026, 5:20PM Outcome of Board Meeting

  • Corona Remedies - Analysts/Institutional Investor Meet/Con. Call Updates

    22 Jul 2026, 2:34PM CORONA Remedies Limited has informed the Exchange about Schedule of meet

  • Corona Remedies - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    22 Jul 2026, 2:31PM Intimation for Schedule of Analysts / Investor Conference

  • Corona Remedies - Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results On Standalone And Co

    17 Jul 2026, 5:36PM Corona Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Corona Remedies Ltd stock 

Name March-26 March-25
Assets 888.83 668.4207
Liabilities 888.83 668.4207
Equity 61.16 61.1601
Gross Profit 293.44 239.9751
Net Profit 184.85 149.0473
Cash From Operating Activities 229.48 190.4942
NPM(%) 13.17 12.45
Revenue 1403.18 1196.4152
Expenses 1109.74 956.4401
ROE(%) 22.9 18.47

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
19 Jun 2026 10 100 0.5 1755.8

Peers

Other companies within the same industry or sector that are comparable to Corona Remedies Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 831.00 5.10 21.02 1141.64 -26.19 0.60
Lotus Eye Hospital and Institute Ltd 114.36 4.53 1633.71 4159.99 0.39 0.00
Vaishali Pharma Ltd 7.81 0.26 24.41 26096.97 15.42 0.00
Astec Lifesciences Ltd 710.45 -2.21 0.00 4457.20 -363.14 0.00

Company Info

Our Company was originally incorporated as `CORONA Remedies Private Limited', a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli. Thereafter, our Company was converted into a public limited company pursuant to a special resolution passed by our Shareholders on October 24, 2024, and consequently, the name of our Company was changed to `CORONA Remedies Limited'. A fresh certificate of incorporation, upon conversion of our Company to a public limited company was issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024.Major events and milestones:2004- Launch of first division, later named as `Pioneer' division in 20102005- Launch of division (multispeciality): Xemx2007- Commencement of production at the first manufacturing plant at Solan, Himachal Pradesh2008- Launch of division (gynaecology): Aarush2013- Launch of division (cardioloy): Wellness2016- Purchased the trademarks "Stelbid" and "Vitneurin" from Glaxo Group Limited- Purchased the trademarks "Dilo DX" and "Dilo-BM" from GlaxoSmithKline Pharmaceuticals Limited2018- Launch of division (cardiovascular diseases): Aura and (gynaecology): Solis- Acquired the trademarks "Obimet", "Obimet-GX", "Obimet SR", "Obimet-V" "Triobimet" and "Thyrocab" (within India) from Abbott India Limited2020- Entered into a strategic alliance with La Chandra Pharmalab Private Limited2021- Commencement of production at the manufacturing plant at Ahmedabad, Gujarat2022- Launch of division (cardiovascular diseases): Radiance and (gynaecology): Solaris2023- Launch of division (urology): Blaze- Purchased the trademark "Myoril" (in India) from Sanofi Healthcare India Private Limited- Received EU GMP accreditation for the manufacturing plant at Ahmedabad, Gujarat 2025 -Acquisition of 7 trademarks from Bayer Zydus Pharma Ltd.

Our Company was originally incorporated as `CORONA Remedies Private Limited', a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli. Thereafter, our Company was converted into a public limited company pursuant to a special resolution passed by our Shareholders on October 24, 2024, and consequently, the name of our Company was changed to `CORONA Remedies Limited'. A fresh certificate of incorporation, upon conversion of our Company to a public limited company was issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024.Major events and milestones:2004- Launch of first division, later named as `Pioneer' division in 20102005- Launch of division (multispeciality): Xemx2007- Commencement of production at the first manufacturing plant at Solan, Himachal Pradesh2008- Launch of division (gynaecology): Aarush2013- Launch of division (cardioloy): Wellness2016- Purchased the trademarks "Stelbid" and "Vitneurin" from Glaxo Group Limited- Purchased the trademarks "Dilo DX" and "Dilo-BM" from GlaxoSmithKline Pharmaceuticals Limited2018- Launch of division (cardiovascular diseases): Aura and (gynaecology): Solis- Acquired the trademarks "Obimet", "Obimet-GX", "Obimet SR", "Obimet-V" "Triobimet" and "Thyrocab" (within India) from Abbott India Limited2020- Entered into a strategic alliance with La Chandra Pharmalab Private Limited2021- Commencement of production at the manufacturing plant at Ahmedabad, Gujarat2022- Launch of division (cardiovascular diseases): Radiance and (gynaecology): Solaris2023- Launch of division (urology): Blaze- Purchased the trademark "Myoril" (in India) from Sanofi Healthcare India Private Limited- Received EU GMP accreditation for the manufacturing plant at Ahmedabad, Gujarat 2025 -Acquisition of 7 trademarks from Bayer Zydus Pharma Ltd.

Parent Organisation

Corona Remedies Ltd.

Founded

27/08/2004

Managing Director

Mr.Nirav Mehta

NSE Symbol

CORONAEQ

FAQ